Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced ...

Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha ...

Finding oneself at an advanced stage of disease is devastating and may diminish one’s hope for the future. Participation in a ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir ... The company will next seek approval from the U.S. Food and Drug Administration (FDA) to market lenacapavir as ...

AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 ...

Citi promotes Summit Therapeutics as a top pick following positive trial data on its ivonescimab antibody, surpassing ...

The Food and Drug Administration (FDA) has cleared an investigational new drug application for the novel treatment, APTN-101, ...

Top-line results were announced from a phase 3 trial evaluating nerandomilast for the treatment of idiopathic pulmonary fibrosis.